On March 17, 2022, the CDE official website showed that AstraZeneca was approved for clinical use with Monalizumab and Oleclumab Injection for injection
AstraZeneca/Daisankyo's blockbuster ADC for the treatment of non-small cell lung cancer received priority review
Time of Update: 2022-05-20
S. FDA for the treatment of patients with unresectable or metastatic non-small cell lung cancer (NSCLC) harboring HER2 mutations .
AstraZeneca's new crown antibody cocktail therapy can provide protection for at least 6 months in high-risk groups
Time of Update: 2022-05-17
AstraZeneca said today that its long-acting antibody cocktail, Evusheld (tixagevimab and cilgavimab), compared with placebo in a late-stage pre-exposure prophylaxis trial, reduced patients with symptomatic COVID-19 infection six months later.
Daiichi Sankyo/AstraZeneca's Enhertu receives FDA breakthrough therapy designation for breast cancer
Time of Update: 2022-05-12
cancer and later-line HER2-positive metastatic breast cancer . >DESTINY-Breast04 is a randomized, open-label, global, multicenter registry Phase III trial evaluating Enhertu (5
AstraZeneca/Daisankyo ADC therapy plans to be included in the priority review of Class 1 new
Time of Update: 2022-05-12
Breast cancer | AstraZeneca/Daiichi Sankyo ADC therapy proposed for priority review> On April 24, the CDE official
The Shenzhen Medical Insurance Bureau arrested 17 people involved in the case and reported AstraZeneca's insurance fraud incident
Time of Update: 2022-05-03
In August 2021, AstraZeneca found in an internal compliance inspection that a small number of employees in Shenzhen had tampered with or participated in tampering with patient test reports, suspected of defrauding medical insurance funds .
AstraZeneca's antibody cocktail Evusheld gets UK MHRA authorisation for COVID-19 pre-exposure prophylaxis
Time of Update: 2022-04-19
The primary data from the ongoing Phase III trial (PROVENT study), which has met its primary endpoint, showed a statistically in the risk of symptomatic COVID-19 in the Evusheld group compared to placebo .
Eli Lilly, BMS, Roche, AstraZeneca lead the most anticipated new drug launch in 2022
Time of Update: 2022-04-16
Lilly needs to go all out . While tirzepatide is expected to be approved first for diabetes indications, Lilly is also eyeing potential use in obesity to challenge Novo Nordisk's Wegovy (semaglutide
AstraZeneca abandoned the new crown vaccine for beta variants and has entered clinical phase 2/3!
Time of Update: 2022-03-08
Given the small genetic differences between the beta variant and the original SARS-CoV-2 virus, AstraZeneca responded by tweaking its first-generation Vaxzevria vaccine .
AstraZeneca's Saphnelo gets EU approval for systemic lupus erythematosus
Time of Update: 2022-03-04
The European approval was supported by the Phase III TULIP-1 and -2 studies and the interim MUSE trial investigating the efficacy and safety of intravenous Saphnelo (anifrolumab) in patients with moderate to severe SLE .
AstraZeneca terminates development of Phase II/III COVID-19 vaccine AZD2816
Time of Update: 2022-03-02
On June 27, 2021, AstraZeneca announced that the first subjects of the Phase II/III clinical trial of AZD2816 had completed the vaccination .
Lusheng and AstraZeneca reached a strategic cooperation to jointly promote ovarian cancer HRD detection in Southeast Asia
Time of Update: 2022-02-26
10, 2021 /PRNewswire/ -- AstraZeneca Singapore and Lucence announce the signing of a strategic collaboration agreement to provide homologous recombination repair for newly diagnosed patients with advanced ovarian cancer in Southeast Asia Defect (HRD) detection .
AstraZeneca reaches deal with Ionis to develop innovative ASO therapy over $3.5 billion
Time of Update: 2022-02-24
html[3] Astrazeneca And Ionis Sign Deal To Develop And Commercialise Eplontersen.
Ovid/AstraZeneca Collaboration to Develop Epilepsy Therapy for Novel Target
Time of Update: 2022-02-24
On January 3, 2022, Ovid Therapeutics announced that it had entered into an exclusive license agreement with AstraZeneca to acquire AstraZeneca's early development stage small molecule library targeting the KCC2 transporter, including lead candidate OV350 .
Focusing on AI and difficult-to-drug targets AstraZeneca reaches two R&D collaborations
Time of Update: 2022-02-23
of innovative targets . Scientists from both companies will use this platform, along with data from multiple sources, to better understand the underlying mechanisms of these diseases and discover
